Navigation Links
Parkinson's disease medication triggers destructive behaviors
Date:4/8/2009

ROCHESTER, Minn. -- A new study conducted at Mayo Clinic reports that one in six patients receiving therapeutic doses of certain drugs for Parkinson's disease develops new-onset, potentially destructive behaviors, notably compulsive gambling or hypersexuality.

VIDEO ALERT: Additional audio and video resources including excerpts from an interview with Dr. J. Michael Bostwick describing the research, are available on the Mayo Clinic News Blog.

The study extends findings from two Mayo case series published in 2005 that reported a connection between dopamine agonist medications and compulsive gambling or hypersexuality.

Dopamine agonists are a class of drugs that include pramipexole and ropinirole. They are commonly used to treat Parkinson's disease, but low doses also are used for restless legs syndrome. They uniquely stimulate brain limbic circuits, which are thought to be fundamental substrates for emotional, reward and hedonistic behaviors.

"The 2005 case series alerted us that something bad was happening to some unfortunate people. This study was done to assess the likelihood that this effect would happen to the average Parkinson's patient treated with these agents," says J. Michael Bostwick, M.D., Mayo Clinic psychiatrist who spearheaded the new study. It is published in the April issue of Mayo Clinic Proceedings.

The researchers analyzed the medical records of patients with Parkinson's disease residing in counties surrounding Rochester, Minn., who received their primary neurological care at Mayo Clinic in Rochester between 2004 and 2006. This group included 267 patients. Of those, 66 were taking dopamine agonists for their Parkinson's disease. Of those 66, 38 were taking the drugs in therapeutic doses (doses expected to be at least minimally beneficial).

The findings were definitive. Seven patients experiencing new-onset compulsive gambling or hypersexuality were taking dopamine agonists in therapeutic doses. None of the other Parkinson's disease patients developed compulsive gambling habits or hypersexuality, including the 28 patients on subtherapeutic dopamine agonist doses or the other 201 patients not taking dopamine agonists. None of the 178 patients treated only with the standard drug for Parkinson's disease, carbidopa/levodopa, developed these behaviors.

"It is crucial for clinicians prescribing dopamine agonists to apprise patients as well as their spouses or partners about this potential side effect. The onset can be insidious and overlooked until life-altering problems develop," says J. Eric Ahlskog, M.D., Ph.D., Mayo Clinic neurologist who co-authored and treated many of the patients in the 2005 study. "It also is worth noting that the affected patients were all taking therapeutic doses. Very low doses, such as those used to treat restless legs syndrome, carry much less risk."

"For some patients, a reduction in the dose of the dopamine agonist may prove to be sufficient treatment," says Dr. Ahlskog, "although total elimination of the offending drug is often necessary."


'/>"/>

Contact: John Murphy
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Smoking may strongly increase long-term risk of eye disease
2. Pot bellies linked to early signs of cardiovascular disease
3. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
4. Radiologists encouraged to look beyond cancer for clinically unseen diseases
5. Use of certain lipid measures not more effective in predicting coronary heart disease
6. Role seen for cannabis in helping to alleviate allergic skin disease
7. New prion protein discovered by Canadian scientists may offer insight into mad cow disease
8. Effectiveness of mouse breeds that mimic Alzheimers disease symptoms questioned
9. New research shows how chronic stress worsens neurodegenerative disease course
10. A new molecular zip code, and a new drug target for Huntingtons disease
11. Stanford study highlights cost-effective method of lowering heart disease risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... ... July 26, 2017 , ... Team Type 1 Foundation, ... medicine for everyone affected by diabetes, is excited to announce the 106 college athletes ... Program. , Established in 2005, the Team Type 1 Foundation has bestowed a ...
(Date:7/26/2017)... BC (PRWEB) , ... July 26, 2017 , ... ... (the “Company” or “Isodiol”) a global cannabis innovator, specializing in the development of ... the period from April 1, 2017 to June 30, 2017. Iso International LLC ...
(Date:7/26/2017)... ... July 26, 2017 , ... The number of adults 65 years or ... ways to improve asthma control in the population are not well described. In a ... Practice), an official journal of the American Academy of Allergy, Asthma & Immunology (AAAAI), ...
(Date:7/25/2017)... MOORE, OK (PRWEB) , ... July 25, 2017 ... ... are proud to announce the launch of their partnership to provide the ... is the first pharmacy-focused platform in the country with the ability to develop ...
(Date:7/25/2017)... ... July 25, 2017 , ... ... provider in the United States, today announced its partnership with financial technology company, ... , The foundation of the solution lies within Hyosung’s superior ATMs, assisted self-service ...
Breaking Medicine News(10 mins):
(Date:7/21/2017)... July 21, 2017  Endo International plc (NASDAQ: ... comprehensive review of its manufacturing network, the Company will ... facilities in Huntsville, Alabama . The ... over the next 12 to 18 months. The ... declining volumes of commoditized products and these restructuring actions ...
(Date:7/15/2017)... PHILADELPHIA , July 15, 2017 Enterin Inc., ... compounds to treat Parkinson,s disease (PD), today announced the completion ... included new investors New Ventures III, as well as the ... "We are absolutely thrilled to have the support of New ... of our investors as validation of the potential of our ...
(Date:7/13/2017)... 2017  New York City-based market research firm Kalorama Information ... aware of.  From new products to new costs, to the ... recently completed study, Potential Pipeline Disruptors . ... 1.  Age-Driven Growth - True Impact Moment Arriving ... the impact the growing population and, to a more extreme ...
Breaking Medicine Technology: